Literature DB >> 16098343

Applications of PET in liver imaging.

Amir H Khandani1, Richard L Wahl.   

Abstract

Fluorodeoxyglucose PET (FDG-PET) imaging has an important role in determining if there are metastases to the liver and whether disease has spread beyond the liver. Such information is critical for planning surgical resections of liver metastases. The ability of FDG-PET quantitatively to estimate metabolic rates makes it an important tool for monitoring. With increasingly broad indications for FDG-PET imaging, it is expected that FDG-PET (and PET-CT) of the liver will play a growing and increasingly important role in detecting and monitoring treatment of tumors involving the liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098343     DOI: 10.1016/j.rcl.2005.05.008

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  4 in total

1.  Quantification of tumour (18) F-FDG uptake: Normalise to blood glucose or scale to liver uptake?

Authors:  Georgia Keramida; Sabina Dizdarevic; Janice Bush; A Michael Peters
Journal:  Eur Radiol       Date:  2015-04-22       Impact factor: 5.315

2.  Hepatic FDG Uptake is not Associated with Hepatic Steatosis but with Visceral Fat Volume in Cancer Screening.

Authors:  Kyoungjune Pak; Seong-Jang Kim; In Joo Kim; Keunyoung Kim; Heeyoung Kim; So Jung Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-21

3.  Respiratory 4D-Gating F-18 FDG PET/CT Scan for Liver Malignancies: Feasibility in Liver Cancer Patient and Tumor Quantitative Analysis.

Authors:  Anson H Y Cheung; Vincent W C Wu; Andy L Y Cheung; Jing Cai
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

4.  Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate.

Authors:  Anne Roivainen; Alexandru Naum; Heikki Nuutinen; Rauli Leino; Heimo Nurmi; Kjell Någren; Riitta Parkkola; Johanna Virtanen; Markku Kallajoki; Harry Kujari; Jari Ovaska; Peter Roberts; Marko Seppänen
Journal:  EJNMMI Res       Date:  2013-02-27       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.